Thinking About Market Cycles & Growth in the Ophthalmology Sector

A panel of Wall Street analysts offer their insights on the future performance of the public markets, including ophthalmology stocks at OIS@AAO in Las Vegas. Participants: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham, currently a Partner, joined Clarus in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors.…

Read More

Envisia Therapeutics

This company, founded as a spin-out of Liquidia Technologies in 2013, began with a $25 million Series A, with the goal of developing the PRINT particle platform for ophthalmic indications. The PRINT platform can be applied to make “very precise drug delivery systems for the eye,” Dr. Yerxa said, as anything that can be manufactured…

Read More

Ophthalmology Innovation Summit Gives Nod to Successful Public Start-ups

Largest ever gathering will showcase recent IPO Companies, early stage companies and speech by Allergan’s CEO LAS VEGAS, NV (PRWEB) NOVEMBER 12, 2015 The seventh annual Ophthalmology Innovation Summit today (OIS) will draw more than 900 clinicians, investors and executives upon the Planet Hollywood Hotel in Las Vegas for a glimpse of the world’s most…

Read More

Understanding Market Cycles: When Could Biotech UnBoom?

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 061″] David Nierengarten, Managing Director, Wedbush Securities, explains how public market cycles could hit biotech and ophthalmology companies. Podcast Guest David Nierengarten, PhD David Nierengarten is a senior biotechnology equity analyst with Wedbush Securities, mainly covering development-stage therapeutic companies. He began his career on the financial side of biotechnology at a…

Read More

Is Auris Still Building a Robot for Cataract Surgery?

Auris Surgical Robotics Inc., a Bay Area medical technology company that had been developing a robotic platform for cataract surgery, just raised $150 million, but is in “stealth” mode as to what the proceeds of the capital infusion will be used for. David Schumer, head of marketing for Auris, would neither confirm nor deny reports…

Read More

Revenue Report Card for Recent IPO Class

As a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to stage an IPO without meaningful revenue. However, most other device companies that have gone public lately have had to prove that customers are buying what they’re selling. And now that…

Read More

CEO Tom Burns Has Even Bigger Plans For Glaukos

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 052″] MIGs leader Glaukos Corp. raised over $100 million in an IPO to expand its already commanding reach in the white hot MIGs Market. Now the company commands a market capitalization close to $1 billion, enriching the venture investors who committed more than $100 million in venture capital to the company.…

Read More

Is pSivida on the verge of megastar status?

With three of the four sustained-release drug delivery products commercially available in the U.S. and Europe, pSivida just might prove Wall Street pundits correct and score some big wins in the ophthalmic space. The Watertown, Mass.-based company’s Durasert technology can deliver drugs to the posterior segment for a predetermined amount of time ranging from months…

Read More

Calhoun Vision Stages Turnaround

Medtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary ophthalmic devices. Oculeve excited Dry Eye leader Allergan enough to warrant a significant acquisition offer, bringing the highly promising neurostim device in-house where it may someday complement Restasis. Now we’re…

Read More

Clarus Delivers Good News With $500m Fund

OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 048″] OIS Co-Chair Emmett Cunningham explains how Clarus will invest new $500m fund in ophthalmology and beyond. Podcast Guest Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals.…

Read More

Investors Move Fast on AERI, AAVL Clinical News

Two presenters at the OIS saw their stock prices shoot in different directions following the release of news related to late-stage clinical trials. On Tuesday, Aerie Pharmaceuticals, received approval from the Food and Drug Administration to change the primary endpoint of its second Phase 3 trial of Rhopressa, its rho kinase (ROCK) inhibitor for reduction…

Read More

Ivantis

The Hydrus Microstent dilates and scaffolds Schlemm’s canal. More than 2,000 people in 21 countries have been treated with the Hydrus, and recruitment for the company’s U.S. pivotal trial is now complete (n=558). When in place, the device creates a cross-sectional stent that increases the cross-sectional diameter of Schlemm’s canal by “about 4-5 times,” Van…

Read More